|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC32
|
|
gptkbp:CASNumber
|
1380723-44-3
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:atezolizumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tecentriq
|
|
gptkbp:indication
|
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:triple-negative_breast_cancer
Small Cell Lung Cancer
hepatocellular carcinoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
PD-L1 inhibitor
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.gene.com/download/pdf/tecentriq_prescribing.pdf
|
|
gptkbp:PubChem_CID
|
DB11595
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
fatigue
cough
decreased appetite
immune-related adverse events
|
|
gptkbp:target
|
PD-L1
|
|
gptkbp:UNII
|
6X9OC3H4II
|
|
gptkbp:bfsParent
|
gptkb:Atezolizumab
gptkb:Roche
|
|
gptkbp:bfsLayer
|
6
|